Heron Therapeutics (Nasdaq: HRTX) withdraws 2026 guidance as CINVANTI patent ruling reshapes plan

Heron Therapeutics, Inc. (Nasdaq: HRTX) reported second-quarter 2026 net revenue of US$37.7 million, up 9 per cent sequentially and roughly 1 per cent above the prior-year comparable, on Monday, 10 August 2026, but the print was overshadowed by a set of unusually direct capital and strategy decisions. The company withdrew its previously issued full-year 2026 guidance of US$173 million to US$183 million in net revenue and US$10 million to US$20 million in Adjusted EBITDA, amended its Hercules Capital credit facility with a US$13.5 million principal paydown at execution and a potential further US$4 million reduction on or before 15 September 2026, paused the sales force expansion that had been slated for the second half, and confirmed it is considering strategic alternatives. The central tension is stark: the Acute Care franchise grew 43.9 per cent year over year and continues to compound, yet a June 2026 US District Court for the District of Delaware ruling invalidating two patent claims covering CINVANTI, the company’s largest single product, has forced management to concede it cannot reliably forecast generic entry. Chief Executive Officer Craig Collard framed the response as balance-sheet reset and strategic optionality rather than operating collapse, but the market treated the guidance withdrawal and the strategic alternatives language as a reset of the equity story itself.

How does Heron Therapeutics’ second-quarter revenue of $37.7 million square with the withdrawal of its 2026 net revenue guidance

The quarter itself was not a disaster. Total net revenue of US$37.7 million rose 9 per cent from the US$34.7 million reported in the first quarter of 2026 and sits fractionally above the US$37.2 million recorded in the comparable prior-year period. The net loss widened to US$5.49 million from US$2.38 million a year earlier, and the six-month net loss of US$13.6 million reversed the US$0.254 million net income Heron Therapeutics posted for the first half of 2025. Basic and diluted loss per share from continuing operations came in at US$0.03 for the quarter and US$0.07 for the half.

The withdrawal of guidance is the more important signal. Heron Therapeutics said three factors drove the decision: the CINVANTI patent ruling and the resulting inability to reliably forecast the timing or terms of potential generic entry on its largest product; the decision to pause the planned Acute Care sales force expansion that the previous operating plan had assumed for the second half; and the initiation of a strategic alternatives review that management is running alongside execution of the current plan. Full-year revenue guidance had implied a step-up from the US$154.9 million achieved in 2025, with Adjusted EBITDA of US$10 million to US$20 million meant to demonstrate scaling operating leverage. Removing that number without offering a replacement range is a considered choice: management is choosing not to defend a mid-case that its own cost and go-to-market assumptions no longer support.

Why does the CINVANTI patent ruling from the District of Delaware sit at the centre of the Heron Therapeutics 2026 reset

CINVANTI, an intravenous formulation of aprepitant for chemotherapy-induced nausea and vomiting, is the anchor product of the Oncology Supportive Care franchise. It generated US$21.8 million of net revenue in the second quarter, down about 10 per cent year over year, and remains the single largest revenue contributor across the portfolio. On 2 June 2026, the US District Court for the District of Delaware ruled that two patent claims covering CINVANTI were invalid. Heron Therapeutics has appealed, meaning the invalidation is not yet final and the timing and terms of any generic entry remain unresolved.

The commercial consequence, however, is already flowing through management’s planning. A patent challenge that survives appeal would expose CINVANTI to at-risk or launched generic competition and compress both the price and the branded share of the intravenous aprepitant market. That is precisely the variable Heron Therapeutics said it cannot reliably forecast, and it is the reason the 2026 guidance came out. For a company with US$154.9 million in 2025 net revenue and a portfolio in which CINVANTI still supplies the majority of quarterly sales, the downside case is measurable enough to matter to covenants, sales-force sizing and cash runway.

What does the amended Hercules Capital credit facility mean for Heron Therapeutics’ balance sheet and covenant runway

The company ended the second quarter with US$42.7 million in cash, cash equivalents and short-term investments. Under the amended Hercules Capital facility, Heron Therapeutics made a US$13.5 million principal reduction at execution, plus associated fees, and may make a further US$4 million principal reduction on or before 15 September 2026. That takes pro forma cash to approximately US$28.5 million after the first payment and, if the September reduction is made, to approximately US$24.3 million.

The trade for that cash is covenant flexibility. Chief Financial Officer Ira Duarte said the amendment establishes monthly minimum revenue, Adjusted EBITDA and cash covenants running through December 2027. A monthly covenant grid rather than quarterly testing is unusually tight; it gives the lender frequent look-through into whether the business is still meeting its plan, and it tightens management’s operating discipline in the same motion. The covenant reset through 2027 is best read as buying time to defend CINVANTI, execute on Acute Care and, if necessary, run a strategic process without triggering a technical default in the interim. It is not, on its own, evidence of financial strength; it is evidence that lender and borrower have agreed on a lower-tolerance framework in exchange for reducing outstanding principal.

How is the Acute Care franchise growth of 43.9 per cent holding up under the wider Heron Therapeutics revenue picture

The Acute Care franchise remains the growth engine and the reason the equity story exists at all. Net revenue increased 43.9 per cent year over year in the second quarter and 38.2 per cent year over year for the six months to 30 June 2026. ZYNRELEF, an extended-release dual-acting local anesthetic combining bupivacaine with a low dose of the non-steroidal anti-inflammatory meloxicam, contributed US$11.1 million in net revenue for the quarter, up 35 per cent year over year and 9 per cent sequentially. APONVIE, an intravenous formulation of aprepitant for postoperative nausea and vomiting, contributed US$4.2 million, up 74 per cent year over year and 26 per cent sequentially. Chief Operating Officer Mark Hensley put total Acute Care sales at US$15.3 million for the quarter.

Two underlying data points frame the growth. ZYNRELEF average daily units grew 19 per cent year over year, which points to a real, if slower than modelled, adoption curve rather than a one-off restocking effect. The IGNITE 2.0 commercial programme now covers roughly 3,150 accounts, compared with about 2,260 under IGNITE 1.0, meaning the addressable footprint is materially wider than it was a year ago. Mark Hensley described ZYNRELEF adoption as a site-by-site, case-by-case curve, and management’s stated focus is converting access into cases and standing protocols at accounts where the product is already on formulary. APONVIE also benefits from a permanent product-specific J-Code, J8502, granted by the Centers for Medicare and Medicaid Services, which streamlines hospital reimbursement and should support continued volume growth.

The disappointment sits between adoption and revenue conversion. Management said outright that key product sales came in below its internal expectations for the quarter, even with the strong year-over-year growth rates. That gap is what the previously planned sales force expansion was meant to close, and it is the same expansion the company has now paused.

Why does pausing the planned sales force expansion signal a real change in Heron Therapeutics’ commercial trajectory

The sales force expansion had been the operational centrepiece of the 2026 growth plan. It was on track for the third quarter of 2026, was assumed in the withdrawn guidance, and was designed to deepen coverage of both formulary and non-formulary accounts in ZYNRELEF and APONVIE. Pausing it in direct response to the Delaware ruling reorders Heron Therapeutics’ short-term priorities: it is now protecting cash for a defence of CINVANTI on appeal, potential covenant management and the strategic alternatives review, rather than accelerating Acute Care case conversion.

The commercial risk is that the pause slows what has been the strongest operating trend in the business. ZYNRELEF and APONVIE growth of 35 per cent and 74 per cent year over year already reflects real momentum, but the sequential 9 per cent uplift in ZYNRELEF revenue, against a wider account footprint under IGNITE 2.0, suggests that per-account penetration remains the main lever. Delayed reps and delayed coverage typically compound into delayed protocol wins. Management can restart the expansion later, but each quarter without it is one where the CINVANTI base is eroding and Acute Care growth has to carry a larger share of the total.

What does the strategic alternatives review at Heron Therapeutics tell shareholders about the range of outcomes now on the table

Craig Collard framed the past ninety days as a period in which the company “reset our balance sheet, tightened our spending, and we are considering strategic alternatives as we continue to execute our current plan.” Strategic alternatives is a defined term in the biotech playbook. It typically covers everything from asset divestitures and licensing transactions to a sale of the company, a reverse merger or a going-private transaction, and it signals that the board has authorised management and, in most cases, an outside adviser to test the market.

For Heron Therapeutics, the range of plausible outcomes is unusually wide because the pieces of the business have different value profiles. The Acute Care franchise is a fast-growing, hospital-channel commercial platform that could sit inside a larger anesthesia or perioperative portfolio. The Oncology Supportive Care franchise is a mature cash-generating asset whose value is now capped by the CINVANTI patent uncertainty. The proprietary Biochronomer drug delivery platform still has technology value that a strategic acquirer might weight differently. Any outcome that unlocks Acute Care value without forcing a fire sale of CINVANTI could improve the base case; any outcome forced by covenant pressure or a failed appeal would carry a lower valuation floor. The commitment to provide quarterly updates on cash, spending and covenant compliance is designed to keep the market informed of where the company sits inside that range as it works through the review.

How does the CINVANTI generic exposure reshape the value case for Heron Therapeutics’ Oncology Supportive Care franchise

The Oncology Supportive Care franchise generated US$22.3 million in net revenue in the second quarter and US$43.4 million in the first half of 2026. That is a meaningful cash contribution and one that, until early June, was still the anchor of the company’s operating model. Post ruling, the calculus changes. Investors have to price CINVANTI on the probability-weighted range of outcomes at the Federal Circuit and, if the ruling stands, on the timing of the first generic entry, the branded share retained through switching frictions, and the price erosion typically observed in intravenous branded oncology support products.

SUSTOL, the extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with certain chemotherapy regimens, remains part of the franchise but is not large enough to offset a material CINVANTI decline. The realistic role of Oncology Supportive Care in the near-term Heron Therapeutics story is therefore to fund the defence of the patent, contribute to covenant compliance and support the strategic review, rather than to underpin a growth thesis of its own.

What are the main execution and market risks that could still unwind the Heron Therapeutics turnaround thesis

Several risks now sit closer to the surface than they did before this update. First, the Federal Circuit appeal on the CINVANTI patents has no scheduled resolution date, and an adverse outcome would confirm the generic path. Second, the monthly covenant grid through December 2027 leaves little room for a sales miss in any single month; missing a monthly minimum revenue, Adjusted EBITDA or cash covenant would put the company back in negotiation with Hercules Capital. Third, the Nasdaq minimum bid price notification received on 26 June 2026, tied to the stock trading below US$1, exposes the company to potential delisting risk unless the price recovers within the standard cure period; a reverse stock split remains a possible path but would be dilutive to trading liquidity and psychological anchoring for retail holders. Fourth, the strategic alternatives review itself is a source of headline risk in both directions, with the possibility of a value-unlocking transaction offset by the possibility of a disappointing outcome.

Market data illustrate how the market has interpreted the balance of these factors. The shares fell to roughly US$0.37 in intraday trading on 10 August 2026, from a prior close of US$0.4908, a decline of about 24.6 per cent during the session, extending a five-day drop of about 27.5 per cent and a year-to-date decline of about 71.5 per cent. Two published analyst opinions maintain an Outperform bias with an average price target of US$2.00, but the spread of over 300 per cent between that consensus and the current share price is itself an indicator of how wide the disagreement now is on how CINVANTI, Acute Care growth and the strategic review will ultimately resolve.

What has improved for Heron Therapeutics, what remains unresolved, and what is the next measurable proof point for the market

What has improved is not the equity narrative but the balance-sheet architecture around it: US$13.5 million of principal is out of the Hercules Capital facility, covenants are reset through the end of 2027, discretionary spending has been tightened, and the Acute Care franchise continues to compound at 43.9 per cent year over year with ZYNRELEF and APONVIE both growing in mid-double to high-double digits. What remains unresolved is the entire top of the funnel: the Federal Circuit appeal on CINVANTI, the pace of ZYNRELEF and APONVIE conversion without a broader sales force, whether the strategic alternatives review yields a transaction, and whether the share price can climb back above US$1 within the Nasdaq cure period. The next measurable proof point is the third-quarter update, which will provide the first monthly-covenant test period, the first read on Acute Care performance without the expanded sales force, and the first structured update on cash, spending and the strategic review.

What should investors track as Heron Therapeutics explores strategic alternatives and defends CINVANTI on appeal

• Heron Therapeutics reported second-quarter 2026 net revenue of US$37.7 million, up 9 per cent sequentially and roughly 1 per cent year over year, but withdrew its full-year 2026 guidance of US$173 million to US$183 million in net revenue and US$10 million to US$20 million in Adjusted EBITDA.
• The trigger was the 2 June 2026 US District Court for the District of Delaware ruling that invalidated two patent claims covering CINVANTI, the company’s largest single product; Heron Therapeutics has appealed, and the timing and terms of potential generic entry remain unresolved.
• The Acute Care franchise grew 43.9 per cent year over year in the quarter and 38.2 per cent in the first half, with ZYNRELEF net revenue of US$11.1 million up 35 per cent year over year and APONVIE at US$4.2 million up 74 per cent, but management said key product sales still came in below internal expectations.
• The Hercules Capital credit facility was amended to reduce outstanding principal by US$13.5 million at execution, with a potential further US$4 million reduction on or before 15 September 2026, taking pro forma cash from US$42.7 million to approximately US$28.5 million now and US$24.3 million after the possible September payment.
• The amended facility installs monthly minimum revenue, Adjusted EBITDA and cash covenants running through December 2027, tightening lender oversight while extending headroom.
• The planned Acute Care sales force expansion, previously scheduled for the second half of 2026, has been paused, removing the main operating catalyst that had underpinned the withdrawn guidance.
• The board is considering strategic alternatives, a wide-ranging review that could yield asset transactions, licensing, a sale of the company, a reverse merger or a going-private path, and Heron Therapeutics will provide quarterly updates on cash, spending and covenant compliance.
• The IGNITE 2.0 commercial programme now covers approximately 3,150 accounts, up from 2,260 under IGNITE 1.0, with APONVIE also benefiting from a permanent product-specific J-Code (J8502) granted by the Centers for Medicare and Medicaid Services.
• The Nasdaq minimum bid price notification received on 26 June 2026 sits alongside intraday trading around US$0.37 on 10 August 2026, a session decline of about 24.6 per cent, a five-day drop of about 27.5 per cent and a year-to-date decline of about 71.5 per cent, framing the near-term delisting risk if the shares do not recover within the standard cure period.
• The next measurable proof points are the third-quarter 2026 update, which becomes the first test of the monthly covenant grid, the progress of the CINVANTI appeal at the Federal Circuit, and any disclosure that emerges from the strategic alternatives review.